EHA 2022 | The impact of early intervention in myelofibrosis
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outlines the results of a study that explored the outcomes of patients with myelofibrosis (MF) treated with ruxolitinib within or after 12 months of diagnosis. The study demonstrated that earlier intervention led to improved outcomes. These findings question current practices in which patients are usually treated when their symptoms increase and raise the question of whether low-risk patients should be treated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
